Analysts Assign $24 Target as Erasca Stock Rallies 305% YTD
Erasca’s stock has climbed 305.17% year to date after analysts set a $24 price target, citing its RAS inhibitor readout as an underpriced catalyst. Investors are pricing in a potential positive clinical outcome that could unlock further upside for the oncology biotech.
1. Analyst Coverage Uptick
Recent research reports have set a $24 price target on Erasca, reflecting optimism around its clinical-stage RAS inhibitor program. Analysts argue that the current share price fails to capture the full probability of a positive readout.
2. Stock Surge Details
Erasca’s shares have surged 305.17% year to date, rising from January 2026 levels as investor interest grows. The rally outpaces most biotech peers and highlights market speculation ahead of the key clinical catalyst.
3. Upcoming RAS Inhibitor Catalyst
The company is awaiting Phase I/II trial results for its RAS inhibitor, a binary event that could significantly re-rate the stock. Analysts expect data disclosure within the next quarters as the pivotal catalyst for further upside.